Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HHS commits $95 million to minorities cancer program
The new initiative, called the community networks program (CNP), was developed by HHS’ National Cancer Institute (NCI), part of the National Institutes of Health. Its aim is to
The new initiative, called the community networks program (CNP), was developed by HHS’ National Cancer Institute (NCI), part of the National Institutes of Health. Its aim is to
Schwarz Pharma is developing fesoterodine, an anti-muscarinic agent, for the treatment of overactive bladder syndrome (OABs) and urinary urge incontinence. Last month, the company successfully completed phase III
American Oriental Bioengineering (AOBO) entered into a letter of intent with Heilongjiang Qitai Pharmaceutical Limited (HQPL) on May 1, 2005 to record AOBO’s intention to acquire HQPL. AOBO
This supply of anthrax vaccine adsorbed (AVA), which is being purchased under the Project BioShield program, will be placed in the US strategic national stockpile where it will
In March, Biovail filed a complete response to address labeling issues raised in an approvable letter received in early January. The approval of Tramadol ODT (tramadol hydrochloride) is
Under the terms of the agreement, InvaGen will develop, manufacture and supply the generic pharmaceutical products exclusively for Able. Able and InvaGen will share the cost of development,
The Generic Pharmaceutical Association (GPhA) said the US Pharmacopeia’s (USP) monograph validates the science underlying generic biopharmaceuticals and shows that biopharmaceuticals can be characterized. “Although the brand industry
The objectives of the phase I clinical trial are to evaluate safety, pharmacokinetics and viral load in patients chronically infected with hepatitis C virus who have failed standard
Mr Clark, formerly president of Merck’s manufacturing division and once chairman and CEO of Medco Health Solutions, was described as an “exceptional leader and strategist” by Mr Bossidy,
Additionally, the company has announced a change in its name from Reata Discovery, Inc to Reata Pharmaceuticals Inc to reflect the clinical status of its drug development programs.